Edwards Lifesciences Corp Quarterly Report for Q3 Ended Sep 30, 2020

Summary

Edwards Lifesciences Corporation reported solid performance for the nine months ended September 30, 2020, with net sales reaching $3.2 billion, a slight increase of 0.7% over the prior year, primarily driven by growth in Transcatheter Aortic Valve Replacement (TAVR) products. While the COVID-19 pandemic presented challenges, impacting procedure volumes and operations, the company demonstrated resilience, with TAVR and Transcatheter Mitral and Tricuspid Therapies (TMTT) procedure volumes showing improvement in the latter half of the second and third quarters. The company also resolved a significant legal matter, settling patent disputes with Abbott Laboratories for an estimated $367.9 million pre-tax charge. Despite this, and other ongoing investments in R&D and share repurchases, Edwards Lifesciences maintained a healthy cash position, with $1,024.0 million in cash and cash equivalents at quarter-end. The company's strategic focus on innovation and patient-centric solutions continues to drive its product development and market position.

Key Highlights

• 1Net sales for the nine months ended September 30, 2020, were $3.2 billion, a 0.7% increase compared to the prior year, driven by TAVR sales.
• 2Transcatheter Aortic Valve Replacement (TAVR) sales increased by 5.3% to $2.1 billion for the nine months ended September 30, 2020.
• 3The company settled patent litigation with Abbott Laboratories, resulting in a $367.9 million pre-tax charge in June 2020.
• 4Despite COVID-19 impacts, procedure volumes for TAVR and TMTT showed recovery in Q2 and Q3 2020 after initial declines.
• 5Research and Development (R&D) expenses remained robust, representing 17.7% of net sales for the first nine months of 2020.
• 6The company repurchased $614.7 million of its common stock during the first nine months of 2020.
• 7Cash and cash equivalents stood at $1,024.0 million as of September 30, 2020.

Frequently Asked Questions